Japan

Astellas Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

PMCA 2021

Participation Not Confirmed

Update your events

Astellas Receives Approval of EVRENZO® in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis

Lead Product(s): Roxadustat

Therapeutic Area: Hematology Product Name: Evrenzo

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: FibroGen, Inc

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 27, 2020

Details:

The MHLW approval of EVRENZO marks the second approval in Japan for roxadustat through the Astellas and FibroGen collaboration, after the therapy was approved and launched for use in adult patients with anemia of CKD on dialysis last year.

Takeda Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

PMCA 2021

Participation Not Confirmed

Update your events

Takeda to Divest TachoSil® to Corza Health for €350 Million

Lead Product(s): Human Fibrinogen,Thrombin

Therapeutic Area: Hematology Product Name: TachoSil

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Corza

Deal Size: $427.0 million Upfront Cash: 427.0 million

Deal Type: Divestment September 16, 2020

Details:

Under the terms of the agreement, upon close, Corza Health will acquire the assets and licenses that support the development and commercialization of TachoSil®, while Takeda will maintain ownership of the manufacturing facility in Linz, Austria.